Livio M, Benigni A, Zoja C, Begnis R, Morelli C, Rossini M, Garattini S, Remuzzi G
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
J Pharmacol Exp Ther. 1989 Jan;248(1):334-41.
Aspirin (ASA) beside inhibiting platelet thromboxane A2 (TxA2) can suppress the formation of renal prostacyclin (PGI2) and prostaglandin E2 (PGE2) which play a crucial role in the control of renal hemodynamics. Previous studies based on urinary PG measurements have suggested that p.o. ASA can spare renal cyclooxygenase. We wanted to establish by direct measurement whether p.o. ASA has a renal sparing effect and to establish to which extent changes in renal cyclooxygenase activity can be predicted measuring urinary excretion of 6-keto-PGF1 alpha and PGE2. Our results showed that in normal rats 10 mg/kg of ASA given p.o. partially inhibits platelet TxA2 formation (measured as serum TxB2) and does not inhibit glomerular and medullary PGI2 and PGE2 synthesis. Higher doses of ASA (30-200 mg/kg) effectively and completely inhibit platelet TxA2 independently if given p.o. or i.v., and also inhibit glomerular and medullary PG synthesis. The kinetics of the effect of ASA on platelet vs. renal cyclooxygenase is different: the inhibition being irreversible in platelets, but rapidly reversible in glomeruli and medulla. Six hours after the administration of 10 and 30 mg/kg i.v. and 30 mg/kg p.o., kidney cyclooxygenase activity recovers completely. This transient inhibition of renal cyclooxygenase is not reflected by urinary excretion of 6-keto-PGF1 alpha and PGE2 (6- and 24-hr collection periods). In conclusion our present results indicate that doses of ASA enough to inhibit platelet TxA2, transiently inhibit glomerular and medullary PGI2 and PGE2. Although the inhibitory effect on platelets is long lasting, the effect on renal cyclooxygenase is transient and rapidly reversible.(ABSTRACT TRUNCATED AT 250 WORDS)
阿司匹林(ASA)除了抑制血小板血栓素A2(TxA2)外,还能抑制肾前列环素(PGI2)和前列腺素E2(PGE2)的形成,而这两种物质在肾血流动力学控制中起着关键作用。以往基于尿中PG测量的研究表明,口服ASA可使肾环氧化酶免受影响。我们想通过直接测量来确定口服ASA是否具有肾脏保护作用,并确定通过测量6-酮-PGF1α和PGE2的尿排泄量能在多大程度上预测肾环氧化酶活性的变化。我们的结果显示,在正常大鼠中,口服10mg/kg的ASA可部分抑制血小板TxA2的形成(以血清TxB2衡量),但不抑制肾小球和髓质PGI2及PGE2的合成。更高剂量的ASA(30 - 200mg/kg),无论口服还是静脉注射,均能有效且完全抑制血小板TxA2,同时也抑制肾小球和髓质PG的合成。ASA对血小板与肾环氧化酶作用的动力学不同:对血小板的抑制是不可逆的,但在肾小球和髓质中是快速可逆的。静脉注射10mg/kg和30mg/kg以及口服30mg/kg的ASA后6小时,肾环氧化酶活性完全恢复。肾环氧化酶的这种短暂抑制并未在6-酮-PGF1α和PGE2的尿排泄量中体现(收集6小时和24小时的尿液)。总之,我们目前的结果表明,足以抑制血小板TxA2的ASA剂量会短暂抑制肾小球和髓质PGI2及PGE2。虽然对血小板的抑制作用持久,但对肾环氧化酶的作用是短暂且快速可逆的。(摘要截选至250字)